HNWAG
ACRS icon

High Net Worth Advisory Group’s Aclaris Therapeutics ACRS Stock Holding History

High Net Worth Advisory Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$8K – 626
2022
Q3 		$8K Hold
500
– – ﹤0.01% 553
2022
Q2 		$7K Hold
500
– – ﹤0.01% 553
2022
Q1 		$9K Buy
+500
New +$6.82K ﹤0.01% 537

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

High Net Worth Advisory Group's ACRS Position: Q4 2022 in Review

High Net Worth Advisory Group sold out of Aclaris Therapeutics (ACRS) in Q4 2022, closing a stake of 500 shares — an estimated $8K sold.

High Net Worth Advisory Group first reported a position in ACRS in Q1 2022 and held it in 3 quarters. The position peaked at $9K in Q1 2022. 128 funds tracked by Wall St. Rank hold ACRS as of Q4 2022.

  • High Net Worth Advisory Group reported no remaining Aclaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 500 Aclaris Therapeutics shares in Q4 2022, an estimated $8K.
  • High Net Worth Advisory Group first reported a position in Aclaris Therapeutics in Q1 2022 and held it in 3 quarters.
  • High Net Worth Advisory Group's Aclaris Therapeutics position peaked at $9K in Q1 2022.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2022.

Based on High Net Worth Advisory Group's 13F filing for Q4 2022, filed 14 Feb 2023.